Skip to main content

FDA Approvals

Payers' Guide, FDA Approvals
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Gazyva (Obinutuzumab) Approved as First-Line Treatment, with Chemotherapy, for Patients with Follicular Lymphoma
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Dysport (AbobotulinumtoxinA) Now FDA Approved for the Treatment of Lower-Limb Spasticity in Adults
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Dupixent (Dupilumab) First Biologic Drug Approved for Patients with Moderate-to-Severe Atopic Dermatitis
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Bavencio (Avelumab) Approved for Metastatic Merkel-Cell Carcinoma and for Urothelial Carcinoma
Lisa A. Raedler, PhD, RPh
Read More
Payers' Guide, FDA Approvals
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
FDA News - August 2017
Read More
FDA Approvals
Novel Assay Provides 100 Times More Information Than Current Liquid Biopsies for Early Cancer Detection
Phoebe Starr
Read More
FDA Approvals
Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer
Wayne Kuznar
Read More
FDA Approvals
Dacomitinib Represents Potential New Targeted Therapy for EGFR Mutation–Positive Lung Cancer
Wayne Kuznar
Read More
Page 30 of 53
Results 291 - 300 of 529